Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. - Wikidata - awgldk - TriplyDB

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

http://www.wikidata.org/entity/Q36839147

about

Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves Ranolazine in Cardiac Arrhythmia Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation New treatment options for late Na current, arrhythmias, and diastolic dysfunction Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo.Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Emerging clinical role of ranolazine in the management of angina.Ranolazine: a new approach to treating an old problem.Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol Ranolazine inhibits voltage-gated mechanosensitive sodium channels in human colon circular smooth muscle cells.Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.Role of late sodium channel current block in the management of atrial fibrillation.The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study.Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967 The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency Ablation Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes.New developments in atrial antiarrhythmic drug therapy.Drug-induced QT-interval prolongation: considerations for clinicians.The pharmaceutical pipeline for atrial fibrillation.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Ranolazine: an antianginal drug with antiarrhythmic properties.A focus on antiarrhythmic properties of ranolazine.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets.Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells.Antiarrhythmic properties of ranolazine--from bench to bedside.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.

P2860

Q24601144-681AD3D8-04FB-4D70-8AD1-5C8DDA637823 Q26784029-BB1447C8-7723-4C08-B99D-A8EFDD44E1C2 Q26863221-D8774786-9DA8-4D0A-8254-B3FC9A6FB39C Q26995558-58F37978-F687-4CD4-942E-4851785912C6 Q27012532-D54DEA5D-C23E-491D-AF7C-CAB76E5A0F9E Q30622882-F6CDEA38-651C-4D0C-AEA3-8A67A3846867 Q30973910-79DFF9CE-EEF6-4B6E-84D4-64FECBD5F8E6 Q33665436-9109736A-C494-49DB-B4B1-1EC0E183F50D Q34181734-F850DDA7-15BB-49FA-8B2B-8E69C12ED03F Q34235939-2C40124E-94FE-48D3-9609-1B801F13A79A Q34457675-41EFC891-DD53-400C-BAB5-D126C926AA53 Q34682939-549B00B3-C1B2-44CD-A594-16A92F63A114 Q34700436-D7DE1616-5B0A-4CB3-BFC8-8F17F6BE7D33 Q35091243-0CDD0D9F-FA7E-4002-9E6D-99F27EE5594F Q35785780-5D6FA850-E238-4B63-ACFE-824AAB38B526 Q35897540-625F3A3B-2DCE-46F8-85BC-2035C3B5F669 Q35897567-4FB843D6-8DD5-4E6F-BC61-F9B2D554463D Q36066445-9EAF2924-A8EB-4853-B2FB-E0AD2CF8C297 Q36534150-F9DE153E-49CE-419C-BE30-6E8E4709236E Q36570112-C26D0F73-4EC5-4509-B859-F4BFFEC85DF6 Q37115123-68F204EA-158C-4CBF-8956-202950E08322 Q37315220-00DEC025-8B8A-494F-9C63-69E9F0281C86 Q37333069-5FC03274-B981-4267-89C3-9BBF310663FC Q37496011-8F8A0613-B31C-4856-A5F5-48DAC77C2CB4 Q37688345-14CA8E58-82C9-4FE3-B72C-6527AACDC248 Q37697498-52D416A4-517D-4EC4-85DC-F4767CC71E67 Q37767425-67FBF1ED-0D5F-480C-8DCB-0D7C7A49ED31 Q37821928-EDF9D0CD-64CF-4AF2-A9C6-DFAD004C6E12 Q37844891-E82F4992-C61B-4EE1-BF06-3CF1FF2EA3BA Q37910205-811D72FE-B08A-4136-8FE6-F36401D06C4C Q38001669-8BDA24C4-6B22-4219-99A7-7E2A90D8F45C Q38074900-9FF7402E-625C-4B46-8BDB-F985844C79C0 Q38226807-1D6711BC-ACA1-4243-BF1B-F6AF9F12AF67 Q38241316-21A950E5-5686-4F97-9352-25409D05394D Q38547436-F8948C94-3E3D-44DB-A7BD-E8ED5F1815AE Q39144763-9087E132-D20A-445A-8182-1241EB23AF70 Q39270116-7D3A3F85-7CD6-43ED-8BCD-4F305677E232 Q39564664-AF781C9D-9DC5-4F2A-8959-3314E4AD5B05 Q39760319-69A8E931-FE4E-4C37-886C-67B8B2FA8A69 Q41121995-49A4A3C5-74DA-42EF-B7A1-C32C90DCD424

P2860

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

http://www.wikidata.org/entity/Q36839147

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

@en

type

label

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

@en

prefLabel

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

@en

P1433

Q36839147-E4ECD10F-426C-4C63-9EE7-A69E53FBE0D2

P1476

Q36839147-74C16206-D9C3-4494-924F-76DE7C877AA6

P2093

Q36839147-545CE933-15E6-4808-ADCC-F97B5DA50687

Q36839147-C8FCBD7F-2A71-443D-ABCB-49C9705EF2CD

Q36839147-D5F1DA81-67D5-48D4-8423-D2773D2709B7

P2860

Q36839147-025C5291-390C-46D5-B05F-892E78861F18

Q36839147-06D941BC-1E40-4172-B161-5BCDDBC8A836

Q36839147-1BA02C5C-7478-4FF4-AAD4-D9659B252E08

Q36839147-22CB48ED-432D-4202-81B4-CDCE08669A90

Q36839147-2B030F87-6F82-4FBD-ABA5-1DC824788F81

Q36839147-2DAF683C-49CF-4647-9301-EC7AFC0B37FD

Q36839147-37482CCC-A503-4795-BC4E-71DE5689E59F

Q36839147-3E09864B-1C19-444C-A195-0CF46D305162

Q36839147-46C5F54F-E543-4D4E-A503-8FAD48AA1CFF

Q36839147-4E14477D-2AF4-41F7-9520-2406FA18AADF

P304

Q36839147-ED598647-D108-45FC-B5BF-2DFD20AACA5C

P31

Q36839147-FE4E0808-A5CD-468B-9AF7-B86311B6B23F

P356

Q36839147-B1EB9DA0-DEC4-4605-A3E0-ABF7A055FAA8

P433

Q36839147-1C46C771-C369-4028-8C0D-5FDDEB48037C

P478

Q36839147-8001844E-824D-47DB-AD3C-C6777402CC7F

P50

Q36839147-63B9504B-2446-40EE-A388-3977BE8D7A8A

Q36839147-C298065A-6B65-400A-B8BE-C97A08CA3EB9

P577

Q36839147-6B419BA0-351F-45E4-96DB-31173C4D7590

P5875

Q36839147-E931C631-926D-4E55-B505-AB3B98D2F854

P698

Q36839147-FBD8CF9B-1CCD-4A9C-8AF5-347077A18E7E

P932

Q36839147-F4D637CF-12C6-4E57-A48E-41BCBC86815B

P356

J.HRTHM.2008.03.018

P1433

P1476

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations

@en

P2093

Aaron Glass

http://www.w3.org/2001/XMLSchema#string

Luiz Belardinelli

http://www.w3.org/2001/XMLSchema#string

Serge Sicouri

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation

Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins

The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart.

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current

Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies.

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.

Electrophysiology of pulmonary veins.

P304

1019-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HRTHM.2008.03.018

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Charles Antzelevitch

P577

2008-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5254347

http://www.w3.org/2001/XMLSchema#string

P698

18598958

http://www.w3.org/2001/XMLSchema#string

P932

2517118

http://www.w3.org/2001/XMLSchema#string